Elanco Animal HealthELAN
▲ PositiveCapitalrelevance
Q2 earnings beat estimates and full-year guidance raised.
Impact on stocks 1
Health Care
Elanco Animal HealthElanco Q2 Earnings Beat Estimates, Raises Full-Year Guidance
Earnings
Elanco reported second-quarter results that beat analyst expectations and raised its full-year guidance. Revenue came in at $1.37 billion versus estimates of $1.31 billion, a 10.2% year-over-year increase, while adjusted EPS of $0.34 beat the $0.27 consensus. The company lifted its full-year revenue guidance to $5.12 billion at the midpoint from $5.05 billion and raised adjusted EPS guidance to $1.13, a 6.6% increase. Management attributed the strong performance to momentum in both Pet Health and Farm Animal businesses, with new products Zenrelia and Credelio Quattro driving growth. Analysts on the earnings call focused on pricing dynamics, revenue contributions from new products, sustainability of Zenrelia's first-line usage, and operating expense trends.
Elanco Animal HealthQ2 earnings beat estimates and full-year guidance raised.